Holen Sie sich die Stockscreener-App
4.20
7.49%
-0.34
Handel nachbörslich:
4.40
0.20
+4.76%
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - GlobeNewswire Inc.
AARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stage - MSN
Aardvark Therapeutics faces investigation after FDA halts its Phase 3 trial, causing stock to plunge. - Pluang
Aardvark Therapeutics shares plunge 56% after halting Phase 3 trial due to safety concerns. - Pluang
We're Keeping An Eye On Aardvark Therapeutics' (NASDAQ:AARD) Cash Burn Rate - Moomoo
FDA halts Aardvark Therapeutics rare disease study - MSN
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - TradingView
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Barchart.com
FDA halts Aardvark Therapeutics' ARD-101 trial over heart safety concerns, stock now valued mainly for cash. - Pluang
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward (NASDAQ:AARD) - Seeking Alpha
AARD stock plummets after hours as cardiac safety concerns trigger FDA hold on late-stage program - MSN
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4 - TipRanks
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Aardvark Therapeutics downgraded to Underperform from Buy at BofA - TipRanks
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug - MedCity News
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.3, Implies 187% Upside - TradingView
B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating - Moomoo
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset - Seeking Alpha
Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application - Moomoo
AARD Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk - Moomoo
AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FDA puts clinical hold on Aardvark’s IND - The Pharma Letter
Aardvark Therapeutics, Inc.Common Stock (Nasdaq:AARD) Stock Quote - The Chronicle-Journal
FDA Halts Aardvark Therapeutics Rare Disease Study - Benzinga
AARD Downgraded by Morgan Stanley -- Price Target Lowered to $3. - GuruFocus
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause - Citeline News & Insights
B. Riley Securities Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics stock tumbles on FDA clinical hold, analyst downgrades - Investing.com Australia
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold - Investing.com
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
AARD Stock Plummets 30.2% Amid U.S.-China Talks - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FDA hold puts Aardvark Prader-Willi drug in limbo - Yahoo Finance
Morgan Stanley Downgrades Aardvark Therapeutics(AARD.US) to Sell Rating, Cuts Target Price to $3 - Moomoo
Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold - Investing.com India
Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $18.45, Implies 174% Upside - TradingView
AARD Faces FDA Clinical Hold on ARD-101 Development - GuruFocus
FDA places full clinical hold on Aardvark’s drug for extreme hunger in Prader-Willi syndrome - WSAU
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program - TipRanks
FDA places clinical hold on Aardvark’s ARD-101 drug trials - Investing.com UK
FDA places clinical hold on Aardvark’s ARD-101 drug trials By Investing.com - Investing.com South Africa
FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome - Reuters
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):